CR10261A - NEW FORMULATIONS - Google Patents

NEW FORMULATIONS

Info

Publication number
CR10261A
CR10261A CR10261A CR10261A CR10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A CR 10261 A CR10261 A CR 10261A
Authority
CR
Costa Rica
Prior art keywords
formulations
new formulations
fpf
variability
therapy
Prior art date
Application number
CR10261A
Other languages
Spanish (es)
Inventor
John Capecchi
James Stefely
Trevor Riley
Original Assignee
3M Innovative Properties Co
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 3M Innovative Properties Co, Glaxo Group Ltd filed Critical 3M Innovative Properties Co
Publication of CR10261A publication Critical patent/CR10261A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

La presente invención se refiere a formulaciones farmacéuticas novedosas en aerosol, procedimientos para su preparación, su uso en terapia, inhaladores de dosis medida que contiene dichas formulaciones y el uso de polimeros biocompatibles para reducir la variabilidad de la uniformidad de contenido y/o para proporcionar fracción de particula fina (FPF) mejorada en dichas formulaciones.The present invention relates to novel pharmaceutical aerosol formulations, methods for its preparation, its use in therapy, metered dose inhalers containing said formulations and the use of biocompatible polymers to reduce the variability of the content uniformity and / or to provide fine particle fraction (FPF) improved in said formulations.

CR10261A 2006-03-22 2008-08-28 NEW FORMULATIONS CR10261A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
CR10261A true CR10261A (en) 2008-11-26

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10261A CR10261A (en) 2006-03-22 2008-08-28 NEW FORMULATIONS

Country Status (18)

Country Link
EP (1) EP2012797A2 (en)
JP (1) JP2009530419A (en)
KR (1) KR20080110854A (en)
CN (1) CN101415428A (en)
AR (1) AR060039A1 (en)
AU (1) AU2007226899A1 (en)
BR (1) BRPI0708798A2 (en)
CA (1) CA2646236A1 (en)
CR (1) CR10261A (en)
EA (1) EA200801854A1 (en)
IL (1) IL193723A0 (en)
MA (1) MA30328B1 (en)
MX (1) MX2008011967A (en)
NO (1) NO20083760L (en)
PE (1) PE20080124A1 (en)
TW (1) TW200803870A (en)
WO (1) WO2007109698A2 (en)
ZA (1) ZA200807682B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045917T2 (en) 2009-02-26 2020-01-28 Glaxo Group Ltd Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021229A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
NZ523958A (en) * 2000-08-05 2004-11-26 Glaxo Group Ltd 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derviative as anti-inflammatory agents
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative

Also Published As

Publication number Publication date
EA200801854A1 (en) 2009-04-28
IL193723A0 (en) 2009-08-03
JP2009530419A (en) 2009-08-27
WO2007109698A2 (en) 2007-09-27
ZA200807682B (en) 2009-11-25
AU2007226899A1 (en) 2007-09-27
CN101415428A (en) 2009-04-22
WO2007109698A3 (en) 2008-12-18
MX2008011967A (en) 2009-01-14
TW200803870A (en) 2008-01-16
KR20080110854A (en) 2008-12-19
CA2646236A1 (en) 2007-09-27
AR060039A1 (en) 2008-05-21
BRPI0708798A2 (en) 2011-06-14
PE20080124A1 (en) 2008-04-21
MA30328B1 (en) 2009-04-01
NO20083760L (en) 2008-12-17
EP2012797A2 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
EA200802012A1 (en) PHARMACEUTICAL PREPARATIONS IN THE FORM OF SOLUTION FOR DOSING INHALERS UNDER PRESSURE
BR112012007182A2 (en) use of desiccant entrained material, metered dose pressurized inhaler dosing valve, metered dose pressurized inhaler closed container system, and method for stabilizing the fine particle mass (mpf) of an inhalation drug formulation
ECSP088403A (en) PHARMACEUTICAL FORMULATION OF ORAL ABSORPTION AND ITS METHOD OF ADMINISTRATION
NZ588913A (en) Liver cancer drug
MX2007008379A (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs.
BRPI0508170A (en) pharmaceutical formulations for dry powder inhalers comprising a low dose potent active ingredient
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
EA200801213A1 (en) NEEDLE FOR CALVING CAPSULES WITH INHALATION POWDER
MX336225B (en) Compositions comprising salbutamol sulphate.
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA101652C2 (en) Composition for inhalation comprising aclidinium for the treatment of asthma and chronic obstructive pulmonary disease
CR10112A (en) MASK OF DUST FLAVOR.
BR112019005168A2 (en) pharmaceutical composition, sealed container, metered dose inhaler, and methods for treating a patient suffering or likely to suffer from a respiratory disorder, for improving the stability of a pharmaceutical composition and the aerosolization performance of a pharmaceutical composition global warming potential of a pharmaceutical composition
MY160979A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
BR112014008602A2 (en) pharmaceutical composition, sealed container, metered dose inhaler, methods for treating a patient suffering or likely to suffer from a respiratory disorder, and method for manufacturing a pharmaceutical composition
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
WO2012040228A3 (en) Aerosol composition for administering drugs
BR112015026053A8 (en) pharmaceutical composition, sealed container, metered-dose inhaler, use of a propellant component, and method for making a pharmaceutical composition
CY1117596T1 (en) PHARMACEUTICAL AIRPORT COMPOSITIONS OF FORMOTEROL AND DIPROPIONAL VEHICLE
MX2015015150A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
MX2015009891A (en) Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy.
CR10261A (en) NEW FORMULATIONS
AR083893A1 (en) USE OF A PHARMACEUTICAL COMPOSITION THAT INCLUDES (S) (3- (1- (1H-IMIDAZOL-4-IL) ETIL) -2-METHYLPENYL) METHANOL TO PREPARE A TOPICAL USEFUL MEDICATION IN REDUCING INTRAOCULAR PRESSURE AND ARTICLE OF CORRESPONDING MANUFACTURE
MX2010007569A (en) Inhalation drug products, systems and uses.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)